COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
Reads0
Chats0
TLDR
Evidence suggests that insulin and dipeptidyl peptidase 4 inhibitors can be used safely in patients with diabetes mellitus and COVID-19; metformin and sodium–glucose cotransporter 2 inhibitors might need to be withdrawn in patients at high risk of severe disease.Abstract:
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin-angiotensin-aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium-glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.read more
Citations
More filters
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Journal ArticleDOI
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda,Kate Maclagan,Simon S. Skene,Martha Bajwa-Joseph,Dawn Letchford,Kashfia Chowdhury,Steve Hibbert,Natalia Budnik,Luca Zampedri,John Dickson,Yazhou Li,Iciar Aviles-Olmos,Thomas T. Warner,Patricia Limousin,Andrew J. Lees,Nigel H. Greig,Susan Tebbs,Thomas Foltynie +17 more
TL;DR: Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure, and effects on everyday symptoms should be examined in longer-term trials.
Journal ArticleDOI
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.
TL;DR: The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology as mentioned in this paper.
Journal ArticleDOI
Clinical Characteristics of COVID-19
TL;DR: Though COVID-19 mainly affects the respiratory system, disease may cause widespread systemic and organ specific symptoms involving gastrointestinal, neurological, cardiovascular, immunological, cutaneous, hematological and coagulation systems.
Journal ArticleDOI
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
Shivaprakash M Rudramurthy,Martin Hoenigl,Martin Hoenigl,Jacques F. Meis,Oliver A. Cornely,Valliappan Muthu,Jean-Pierre Gangneux,John R. Perfect,Arunaloke Chakrabarti,Ecmm,Isham +10 more
TL;DR: In this article, the authors provided a comprehensive document to help clinicians in managing COVID-19-associated mucormycosis (CAM) globally, driven particularly by low and middle-income countries.
References
More filters
Journal ArticleDOI
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Bin Cao,Yeming Wang,Danning Wen,Wen Liu,Jingli Wang,Guohui Fan,Lianguo Ruan,Bin Song,Yanping Cai,Ming Wei,Xingwang Li,Jia'an Xia,Nanshan Chen,Jie Xiang,Ting Yu,Tao Bai,Xuelei Xie,Li Zhang,Caihong Li,Ye Yuan,Hua Chen,Huadong Li,Hanping Huang,Shengjing Tu,Fengyun Gong,Ying Liu,Yuan Wei,Chongya Dong,Fei Zhou,Xiaoying Gu,Jiuyang Xu,Zhibo Liu,Yi Zhang,Li Hui,Lianhan Shang,Ke Wang,Kunxia Li,Xia Zhou,Xuan Dong,Zhaohui Qu,Sixia Lu,Xujuan Hu,Shunan Ruan,Shanshan Luo,Jing Wu,Lu Peng,Fang Cheng,Lihong Pan,Jun Zou,Chunmin Jia,Juan Wang,Xia Liu,Shuzhen Wang,Xudong Wu,Qin Ge,Jing He,Haiyan Zhan,Fang Qiu,Li Guo,Chaolin Huang,Thomas Jaki,Frederick G. Hayden,Peter Horby,Dingyu Zhang,Chen Wang +64 more
TL;DR: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Journal ArticleDOI
Clinical and immunological features of severe and moderate coronavirus disease 2019.
Guang Chen,Di Wu,Wei Guo,Yong Cao,Da Huang,Hongwu Wang,Tao Wang,Xiaoyun Zhang,Huilong Chen,Haijing Yu,Xiaoping Zhang,Minxia Zhang,Shiji Wu,Jianxin Song,Tao Chen,Meifang Han,Shusheng Li,Xiaoping Luo,Jianping Zhao,Qin Ning +19 more
TL;DR: The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production, which may be of importance due to their correlation with disease severity in COVID-19.
Journal ArticleDOI
Estimates of the severity of coronavirus disease 2019: a model-based analysis.
Robert Verity,Lucy C Okell,Ilaria Dorigatti,Peter Winskill,Charles Whittaker,Natsuko Imai,Gina Cuomo-Dannenburg,Hayley A Thompson,Patrick G T Walker,Han Fu,Amy Dighe,Jamie T. Griffin,Marc Baguelin,Sangeeta N. Bhatia,A Boonyasiri,Anne Cori,Zulma M. Cucunubá,Richard G. FitzJohn,Katy A. M. Gaythorpe,W Green,Arran Hamlet,Wes Hinsley,Daniel J Laydon,Gemma Nedjati-Gilani,Steven Riley,Sabine L. van Elsland,Erik M. Volz,Haowei Wang,Y Wang,Xiaoyue Xi,Christl A. Donnelly,Christl A. Donnelly,Azra C. Ghani,Neil M. Ferguson +33 more
TL;DR: These early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease and show a strong age gradient in risk of death.
Journal ArticleDOI
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Jing Yang,Ya Zheng,Xi Gou,Ke Pu,Zhaofeng Chen,Qinghong Guo,Rui Ji,Haojia Wang,Yuping Wang,Yongning Zhou +9 more
TL;DR: The prevalence of comorbidities in infected patients and risk factors for severe compared with non-severe patients are assessed to help the health sector guide vulnerable populations and assess the risk of deterioration.
Journal ArticleDOI
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Keiji Kuba,Yumiko Imai,Shuan Rao,Hong Gao,Feng Guo,Bin Guan,Yi Huan,Peng Yang,Yanli Zhang,Wei Deng,Linlin Bao,Binlin Zhang,Guang Liu,Zhong Wang,Mark C. Chappell,Yanxin Liu,Dexian Zheng,Andreas Leibbrandt,Teiji Wada,Arthur S. Slutsky,Depei Liu,Chuan Qin,Chengyu Jiang,Josef M. Penninger +23 more
TL;DR: A molecular explanation why SARS-CoV infections cause severe and often lethal lung failure and suggest a rational therapy for SARS and possibly other respiratory disease viruses is provided.
Related Papers (5)
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.
Lihua Zhu,Zhi-Gang She,Xu Cheng,Juan Juan Qin,Xiao Jing Zhang,Jingjing Cai,Fang Lei,Haitao Wang,Jing Xie,Wenxin Wang,Haomiao Li,Peng Zhang,Xiaohui Song,Xi Chen,Xiang Mei,Chaozheng Zhang,Liangjie Bai,Da Xiang,Ming Ming Chen,Yanqiong Liu,Youqin Yan,Mingyu Liu,Weiming Mao,Jinjing Zou,Liming Liu,Guohua Chen,Pengcheng Luo,Bing Xiao,Changjiang Zhang,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Ping Ye,Jun Yang,Yufeng Yuan,Xiaodong Huang,Jiao Guo,Bing Hong Zhang,Hongliang Li +43 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more